Table 5.
Overview of polymorphisms in toll-like receptor genes encoding receptors and association with cervical neoplasia risk.
| Gene | Polymorphisma | Cohort | Cases (n) | Population | Distribution | Risk (OR, 95% CI); PAFb,c,d | Reference |
|---|---|---|---|---|---|---|---|
| TLR2 | c.+613T>C (rs3804100) | CIN III Cervical cancer |
470 | Costa Rican | Genotypes |
TC: 0.61 (0.39–0.95) CC: 0.56 (0.09–3.50) TC/CC: 0.61 (0.40–0.93) |
[36] |
|
| |||||||
| TLR4 | c.+936C>T (rs4986791) | Cervical cancer | 150 | North Indian | Genotypes | Overall CT: 1.50 (0.72–2.92) TT: 2.20 (0.20–24.76) Stage II CT: 2.50 (1.03–6.12); 12.5% TT: - Stage III CT: 1.30 (0.54–2.97) TT: 4.20 (0.37–47.64) |
[37] |
|
| |||||||
| TLR9 | c.+2848G>A (rs382140) | Cervical cancer | 120 | Chinese Han | Alleles | A: 7.001 (2.422–20.23); 10.7% | [38] |
| Genotypes |
GA: 6.929 (1.534–33.30); 10.0% AA: 7.918 (1.797–64.52); 5.9% GA/AA: 7.259 (2.104–25.05); 15.8% |
||||||
| 426 | Polish | Genotypes |
GA: 1.443 (1.019–2.043); 16.6% AA: 1.237 (1.016–1.507); 5.0% GA/AA: 1.345 (0.976–1.855) |
[39] | |||
|
| |||||||
| TLR9 | c.-1486T>C (rs187084) | Cervical cancer | 712 | Chinese | Genotypes |
TC: 1.28 (1.01–1.62) TC/CC: 1.24 (1.01–1.53) |
[40] |
| 426 | Polish | Genotypes |
TC: 1.371 (1.021–1.842); 13.0% CC: 1.300 (1.016–1.507); 4.4% TC/CC: 1.448 (1.099–1.908); 20.7% |
[39] | |||
n: number of cases; OR: odds ratio; 95% CI: 95% confidence interval; CIN: cervical intraepithelial neoplasia; PAF: population attributable fraction.
aNucleotide variation and dbSNP reference number.
bOR relative to major allele or major allele homozygotes.
cPAF listed if OR > 1.00.
dSignificant associations listed in bold.